NewsStackNewsStack
Daily Brief: Which companies are hyping vs delivering: red flags, real signals and repeat offenders, free daily.

Custom Health Achieves 220% Revenue Increase to US$14.4 Million in Q3-2026

16 Nov 2026🟠 Likely Overhyped
Share𝕏inf

Revenue tripled but losses widened as Custom Health ramps up acquisitions and capital raises.

What the company is saying

Custom Health Holdings Inc. is highlighting a transformative quarter, with CEO Shane Bishop emphasizing that Q3-2026 is the first full period to include InnovativeRx, driving quarterly revenue to US$14.4 million—over three times last year's level. The company frames its narrative around scale, integration, and the strategic importance of bringing Spencer Health Solutions in-house, completed in September for up to US$25.0 million. Management stresses organic growth, citing a 27% year-over-year revenue increase at InnovativeRx, and positions the acquisition of Spencer as a move to control core technology. CFO Jason Nalewany attributes the 220% revenue surge and 124% gross profit growth to acquisitions, but acknowledges the gross margin decline to 34.1% due to a higher pharmacy revenue mix. The company openly states that net loss increased to US$11.7 million, driven by higher finance costs and a US$2.4 million loss on debt modification. Custom Health also points to leadership strengthening, early program results with BKC Pain Specialists, and a focus on operational efficiency and disciplined capital allocation. The tone is confident and growth-oriented, but acknowledges ongoing integration and margin challenges.

What the data suggests

The disclosed numbers show Custom Health's revenue from continuing operations soared 220% year-over-year to US$14.4 million in Q3-2026, with pharmacy revenue accounting for US$13.3 million and clinical and technology services US$1.1 million. Gross profit rose 124% to US$4.9 million, but gross margin fell from 48.7% to 34.1%, reflecting a shift toward lower-margin pharmacy sales post-InnovativeRx acquisition. Adjusted EBITDA loss narrowed slightly to US$3.4 million from US$3.8 million, but the IFRS net loss widened sharply to US$11.7 million, primarily due to higher finance costs and a US$2.4 million loss on debt modification. InnovativeRx contributed US$10.3 million in revenue, up 27% year-over-year. The company completed the Spencer Health Solutions acquisition for up to US$25.0 million (US$1.5 million cash, US$23.5 million in pre-funded warrants), and signed a binding letter of intent to acquire Evergreen Pharmacy for US$3,500,000 in cash (US$175,000 indemnity holdback), with Evergreen posting unaudited 2025 revenue of US$78.8 million and normalized EBITDA of US$0.6 million. Financing activities included a public offering raising C$10,338,144 at C$4.95 per unit, each with a warrant at C$5.90 for 60 months, and a pending C$10,000,000 private placement. Shares outstanding rose 66% to 26,147,000. While revenue growth is strong, profitability remains elusive, and dilution is substantial.

Analysis

The announcement presents strong revenue and gross profit growth, with realised figures for Q3-2026 and detailed acquisition and financing activities. However, despite the positive tone and operational momentum, the company remains loss-making, with an IFRS net loss of US$11.7 million and an adjusted EBITDA loss of US$3.4 million. The gross margin has declined year-over-year, and the increase in net loss is attributed to higher finance costs and a debt modification loss. Several forward-looking statements relate to the intended use of proceeds and pending private placement, which are not yet realised. The capital intensity is high, with significant recent and pending acquisitions and ongoing equity raises, but the immediate earnings impact is negative or deferred. The narrative is somewhat inflated by emphasizing growth and integration focus, while the underlying profitability remains weak and dilution is substantial.

Risk flags

  • ●Profitability risk is high: despite a 220% revenue increase, the company posted an IFRS net loss of US$11.7 million, up from US$6.3 million, due to rising finance costs and a US$2.4 million loss on debt modification. The path to profitability remains unclear, and ongoing losses could require further dilution or debt.
  • ●Margin compression risk is evident: gross margin fell from 48.7% to 34.1% year-over-year, driven by a higher proportion of lower-margin pharmacy revenue after the InnovativeRx acquisition. This trend could persist as the business scales, limiting operating leverage.
  • ●Integration and execution risk is material: the company is simultaneously integrating multiple acquisitions (InnovativeRx, Spencer Health Solutions) and pursuing another (Evergreen Pharmacy), increasing operational complexity and the risk that expected synergies or efficiencies may not materialize.
  • ●Dilution and capital intensity risk is significant: shares outstanding rose 66% year-over-year to 26,147,000, with further dilution possible from the pending private placement, shelf prospectus (up to C$200 million), and warrant exercises. This could erode per-share value if not matched by earnings improvement.
  • ●Acquisition completion risk remains: the Evergreen Pharmacy deal is at the binding LOI stage, not closed, and is subject to due diligence and regulatory approval. There is no guarantee the transaction will complete on the proposed terms or timeline.

Bottom line

Custom Health is aggressively scaling through acquisitions and capital raises, with Q3-2026 revenue tripling to US$14.4 million and gross profit up 124%, but profitability remains out of reach as net loss widened to US$11.7 million. The company is betting on integration and technology control, having completed the Spencer Health Solutions buyout and targeting Evergreen Pharmacy, which itself posted US$78.8 million in unaudited 2025 revenue but only US$0.6 million in normalized EBITDA. Financing activity is heavy, with a recent C$10.3 million public offering, a pending C$10 million private placement, and a shelf prospectus for up to C$200 million, resulting in a 66% increase in shares outstanding. The gross margin decline and persistent losses highlight the challenge of converting scale into sustainable profitability. Investors should focus on whether integration delivers real operating leverage and if future acquisitions can be absorbed without further margin erosion or dilution. The most important takeaway is that while growth is rapid, the business model's ability to generate profits at scale remains unproven.

Track record

NewsStack has analysed 2 announcements from CHLT since October 2026.

Likely Overhyped: 1Routine Noise: 1

Previous CHLT verdicts

Announcement summary

(TSX:CHLT) Custom Health Holdings Inc. announced its consolidated financial results for the fiscal third quarter ended September 30, 2026. The company reported quarterly revenue from continuing operations of US$14.4 million in Q3-2026, representing a 220% increase compared to US$4.5 million in Q3-2025. Pharmacy revenue was US$13.3 million, while Clinical and Technology services revenue was US$1.1 million. Gross profit for Q3-2026 was US$4.9 million, up 124% from US$2.2 million in Q3-2025. Gross margin was 34.1% in Q3-2026, compared to 48.7% in Q3-2025. Adjusted EBITDA loss was US$3.4 million in Q3-2026, compared to a loss of US$3.8 million in Q3-2025. IFRS net loss from continuing operations was US$11.7 million in Q3-2026, compared to US$6.3 million in the prior year, with the increase driven primarily by higher finance costs and a US$2.4 million loss on modification of debt. InnovativeRx contributed US$10.3 million in revenue in Q3-2026, a 27% year-over-year increase. On July 22, 2026, Custom Health announced a binding letter of intent to acquire Evergreen Pharmacy LLC, a specialty pharmacy in West Allis, Wisconsin, licensed in Wisconsin, Illinois, and Michigan, which generated unaudited revenue of approximately US$78.8 million and Normalized EBITDA of US$0.6 million for fiscal 2025. The proposed purchase price for Evergreen is US$3,500,000 in cash, subject to a US$175,000 indemnity holdback. On September 8, 2026, Custom Health completed its acquisition of Spencer Health Solutions, effective September 4, 2026, following a binding agreement on August 5, 2026, and conditional TSX approval on August 25, 2026. The total consideration for Spencer was up to approximately US$25.0 million, consisting of up to US$1.5 million in cash and US$23.5 million in pre-funded warrants. On October 20, 2026, Custom Health highlighted early results from its program with BKC Pain Specialists & Regenerative Medicine Clinic in Ohio. On October 21, 2026, Mike Palackdharry was appointed Chief Commercial and Strategy Officer and Christina Garcia was appointed Chief Compliance and Regulatory Officer. On November 5, 2026, Custom Health filed and obtained a receipt for a final short form base shelf prospectus with Canadian securities regulators, allowing the company to offer up to C$200 million of securities over a 25-month period. On November 13, 2026, the company closed a public offering of 2,088,514 units at C$4.95 per unit for aggregate gross proceeds of C$10,338,144, with each unit consisting of one common share and one warrant exercisable at C$5.90 for 60 months. A concurrent non-brokered private placement of units on the same terms for gross proceeds of up to approximately C$10,000,000 remains subject to completion and TSX approval. Net proceeds are expected to be used for acquisition payments, transaction costs, debt repayments, general and administrative expenses, and working capital. As of September 30, 2026, shares issued and outstanding totaled 26,147,000, up 66% from 15,765,000 a year earlier. Custom Health will hold a conference call and webcast to discuss its results on November 17, 2026, at 11:00 am EST.

Disagree with this article?

Ctrl + Enter to submit